Neurorehabilitation News

The FDA has granted 510(k) clearance to a radiology artificial intelligence firm for triage and notification of obstructive hydrocephalus on non-contrast brain CT scans, according to a release.

PHILADELPHIA — Older adults who sustained a prior head injury were nearly two times as likely to sustain a future fall compared with those who did not have a prior head injury, according to a poster presentation.

PHILADELPHIA — A genetic risk test for patients with multiple sclerosis can identify drugs that may lead to development of progressive multifocal leukoencephalopathy, per data presented at the American Neurological Association annual meeting.

PHILADELPHIA — Many patients with mild traumatic brain injury have central sensitization, a pain that requires a different therapeutic approach than nociceptic pain, according to a study by Christopher File, BSA, and colleagues.

A single dose of psilocybin resulted in clinically and statistically significant reductions in depressive symptoms and functional disability compared with placebo in patients with major depressive disorder, according to a phase 2 study.

A global clinical-stage specialty biopharmaceutical company has announced positive topline results from its study of its investigational therapeutic AM0-02 to treat children and adolescents with congenital myotonic dystrophy.

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

A global clinical-stage biopharmaceutical company announced positive biomarker data from its exploratory phase 1 electroencephalogram biomarker study of novel and selective Kv7.2/Kv7.3 activator BHV-700 to treat epilepsy.

The first patient has been dosed in a clinical trial with electron accelerator-produced Cu-67, according to a Wisconsin-based company specializing in radiopharmaceuticals for therapeutic and medical imaging applications announced.

A Philadelphia-area contract research organization has announced completion of a phase 1 clinical trial of CMX-2043, Ischemix Inc.’s novel, proprietary cytoprotective drug candidate to treat acute traumatic brain injury.